The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), ...

Addressing all aspects of healthcare maintenance in ulcerative colitis (UC) — one of two major types of inflammatory bowel ...

We have access to serum samples via my mentor Jean-Frederic Colombel -- who is the PI [principal investigator] of the PREDICTS study-- up to 10 years before Crohn's disease or ulcerative colitis ...

Johnson & Johnson seeks US FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis: Spring House, Pennsylvania Monday, November 25, 2024, 11:00 Hrs [IST] ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis ...

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...

July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...

More than 100,000 young Americans under the age of 20 live with inflammatory bowel disease, a CDC-funded study has revealed.

Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application to the FDA seeking approval of a ...

A groundbreaking study published today in Gastroenterology provides the most comprehensive assessment to date of pediatric inflammatory bowel disease (IBD) prevalence in the United States.

The prevalence of inflammatory bowel disease in U.S. children under 20 is increasing, with over 100,000 affected, revealing ...